Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merlin L Robb

Showing results (321-330 of 358) with videos related to

Pageof 36
Sort By:
Plos Pathogens|December 8, 2020
RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Eclinicalmedicine|November 8, 2023
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country studyGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Plos Pathogens|March 2, 2021
Correction: RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Nature Communications|May 25, 2026
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
The Journal of Clinical Investigation|August 9, 2014
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S Li, Peter B Gilbert, Georgia D Tomaras, et al.
Science Translational Medicine|September 20, 2019
Immune correlates of the Thai RV144 HIV vaccine regimen in South AfricaGlenda E Gray, Ying Huang, Nicole Grunenberg, et al.
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
Virus Evolution|September 17, 2021
RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infectionEric Lewitus, Eric Sanders-Buell, Meera Bose, et al.
Science Translational Medicine|April 2, 2025
Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filovirusesThembi Mdluli, Suzanne Wollen-Roberts, Mélanie Merbah, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Pageof 36

Showing results (321-330 of 358) with videos related to

Sort By:
Pageof 36
Plos Pathogens|December 8, 2020
RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Eclinicalmedicine|November 8, 2023
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country studyGustavo H Dayan, Nadine Rouphael, Stephen R Walsh, et al.
Plos Pathogens|March 2, 2021
Correction: RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Nature Communications|May 25, 2026
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
The Journal of Clinical Investigation|August 9, 2014
FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trialShuying S Li, Peter B Gilbert, Georgia D Tomaras, et al.
Science Translational Medicine|September 20, 2019
Immune correlates of the Thai RV144 HIV vaccine regimen in South AfricaGlenda E Gray, Ying Huang, Nicole Grunenberg, et al.
The Lancet. HIV|June 15, 2018
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trialLinda-Gail Bekker, Zoe Moodie, Nicole Grunenberg, et al.
Virus Evolution|September 17, 2021
RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infectionEric Lewitus, Eric Sanders-Buell, Meera Bose, et al.
Science Translational Medicine|April 2, 2025
Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filovirusesThembi Mdluli, Suzanne Wollen-Roberts, Mélanie Merbah, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Pageof 36